|Table of Contents|

The preliminary study of preoperational plasma VEGF/sVEGFR-1 ratio significance in operable non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 02
Page:
232-236
Research Field:
Publishing date:

Info

Title:
The preliminary study of preoperational plasma VEGF/sVEGFR-1 ratio significance in operable non-small cell lung cancer
Author(s):
Hu Mingming1; Hu Ying1; Gao Guangkuo2; Han Yi3; Li Baolan1
1.General Medicine Department；2.Anesthesia Department；3.Thoracic Surgery Department,Beijing Chest Hospital of Capital Medical University,Beijng 101149,China.
Keywords:
non-small cell lung cancer; vascular endothelial growth factor; soluble vascular endothelial growth factor receptor-1; overall survival
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2020.02.012
Abstract:
Objective:To evaluate the preoperational plasma level of VEGF and sVEGFR-1 in operable non-small lung cancer (NSCLC) patients,and then explore their prognostic significance.Methods:We examined preoperational plasma level of VEGF and sVEGFR-1 of 98 operable NSCLC patients by commercially available enzyme-link immunosorbent assay (ELISA).Correlation between these values and clinical factors of these patients,including histopathological features and overall survival,was analyzed.Results:Neither the preoperational level of VEGF nor sVEGFR1 was correlated with any clinical factors.In univariate and multivariate survival analysis,age,pTNM stage and the VEGF/sVEGFR-1 ratio were independent predictors for operable NSCLC patients' survival (HR=1.347,95%CI：1.068~1.699).Conclusion:Preoperational plasma VEGF/sVEGFR-1 ratio was an independent predictor of poor survival of patients in operable NSCLC.Its significance should be considered in operable NSCLC patients.

References:

［1］Jingjing Qu,Yongchang Zhang,Xue Chen,et al.Newly developed anti-angiogenic therapy in non-small cell lung cancer［J］.Oncotarget,2018,9(11):10147-10163.
［2］Zhao S,Ma D,Dai H,et al.Biologically inhibitory effects of VEGF siRNA on endometrial carcinoma cells［J］.Arch Gynecol Obstet,2011,284(6):1533-1541.
［3］Bhuvaneswari R,Yuen GY,Chee SK,et al.Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model［J］.Lasers Surg Med,2011,43(7):651-662.
［4］ Lichtenberger BM,Tan PK,Niederleithner H,et al.Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development［J］.Cell,2010,140(2):268-279.
［5］ Yu Y,Lee P,Ke Y,et al.A humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft models［J］.PLoS One,2010,5(2):e9072.
［6］Nakano Takayuki,Tanimura Keiko,Uchino Junji,et al.Advanced non-small cell lung cancer in elderly patients:Patient features and therapeutic management［J］.Biomed Res Int,2018:8202971.
［7］Qiao M,Jiang T,Zhou C.Shining light on advanced NSCLC in 2017:Combining immune checkpoint inhibitors［J］.J Thorac Dis,2018,10(Suppl 13):S1534-S1546.
［8］Wu FT,Stefanini MO,Mac Gabhann F,et al.A systems biology perspective on sVEGFR1:Its biological function,pathogenic role and therapeutic use［J］.J Cell Mol Med,2010,14(3):528-552.
［9］Otrock ZK,Makarem JA,Shamseddine AI.Vascular endothelial growth factor family of ligands and receptors:Review［J］.Blood Cells Mol Dis,2007,38(3):258-268.
［10］Owen LA,Uehara H,Cahoon J,et al.Morpholino-mediated increase in soluble Flt-1 expression results in decreased ocular and tumor neovascularization［J］.PLoS One,2012,7(3):e33576.
［11］Collet G,Lamerant-Fayel N,Tertil M,et al.Hypoxia-regulated overexpression of soluble VEGFR2 controls angiogenesis and inhibits tumor growth［J］.Mol Cancer Ther,2014,13(1):165-178.
［12］Wu FT,Stefanini MO,Mac Gabhann F,et al.A compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trap［J］.PLoS One,2009，4(4):e5108.
［13］Bando H,Weich HA,Brokelmann M,et al.Association between intratumoral free and total VEGF,soluble VEGFR-1,VEGFR-2 and prognosis in breast cancer［J］.Br J Cancer,2005，92(3):553-561.
［14］Toi M,Bando H,Ogawa T,et al.Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer［J］.Int J Cancer,2002,98(1):14-18.
［15］ Chang YT,Chang MC,Wei SC,et al.Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer［J］.Pancreas,2008,37(2):145-150.
［16］Aref S,El Sherbiny M,Goda T,et al.Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come［J］.Hematology,2005,10(2):131-134.
［17］ Shibuya M,Yamaguchi S,Yamane A,et al.Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family［J］.Oncogene,1990,5(4):519-524.
［18］Stampalija T,Chaiworapongsa T,Romero R,et al.Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia［J］.J Matern Fetal Neonatal Med,2013,26(14):1359-1370.
［19］Kar M.Role of biomarkers in early detection of preeclampsia［J］.J Clin Diagn Res,2014,8(4):BE01-4.
［20］Mynard SE,Min JY,Merchan J,et al.Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction,hypertension,and proteinuria in preeclampsia［J］.J Clin Invest,2003,111(5):649-658.
［21］ Mori A,Arii S,Furutani M,et al.Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes［J］.Gene Ther,2000,7(12):1027-1033.
［22］ Ogawa T,Takayama K,Takakura N,et al.Anti-tumor angiogenesis therapy using soluble receptors:Enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor［J］.Cancer Gene Ther,2002,9(8):633-640.
［23］Roda JM,Sumner LA,Evans R,et al.Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis［J］.J Immunol,2011,187(4):1970-1976.
［24］Uehara H,Cho Y,Simonis J,et al.Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR)［J］.FASEB J,2013,27(1):76-85.

Memo

Memo:
中共北京市委组织部优秀人才培养资助（编号：2017000021469G256）
Last Update: 2019-11-29